Pharmacogenomics of Antihypertensive Treatment a Clinical Pharmacological Studies of Digoxin Treatment
暂无分享,去创建一个
[1] A. Redfors. The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation. , 2009, Acta Medica Scandinavica.
[2] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[3] M. Rosenqvist,et al. Comorbidity and Myocardial Dysfunction Are the Main Explanations for the Higher 1-Year Mortality in Acute Myocardial Infarction With Left Bundle-Branch Block , 2004, Circulation.
[4] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[5] M. Mack,et al. On-Pump Versus Off-Pump Coronary Artery Bypass Surgery in a Matched Sample of Women: A Comparison of Outcomes , 2004, Circulation.
[6] K. Michaëlsson,et al. Beta1‐adrenergic receptor gene polymorphisms and response to Beta1‐adrenergic receptor blockade in patients with essential hypertension , 2004, Clinical cardiology.
[7] P. Lindenauer,et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery , 2004, JAMA.
[8] P. Armstrong,et al. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. , 2004, Clinical therapeutics.
[9] Roger D. White,et al. Admission Predictors of In-Hospital Mortality and Subsequent Long-Term Outcome in Survivors of Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: A Population-Based Study , 2004, Cardiology.
[10] M. Domanski,et al. Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.
[11] H. Melhus,et al. Transforming growth factor β1 genotype and change in left ventricular mass during antihypertensive treatment–results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (Silvhia) , 2004 .
[12] M. Esler,et al. Sympathetic Augmentation in Hypertension: Role of Nerve Firing, Norepinephrine Reuptake, and Angiotensin Neuromodulation , 2004, Hypertension.
[13] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[14] Martin J Firth,et al. Association between antenatal cytokine production and the development of atopy and asthma at age 6 years , 2003, The Lancet.
[15] K. Michaëlsson,et al. BMC Cardiovascular Disorders BioMed Central , 2003 .
[16] G. Dorn,et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.
[17] M. Woodward,et al. The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition , 2003, Hypertension.
[18] M. Esler,et al. Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy , 2003, Circulation.
[19] Ihab Hajjar,et al. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.
[20] A. Mitchell,et al. Effect of the C825T Polymorphism of the G Protein β3 Subunit on the Systolic Blood Pressure–Lowering Effect of Clonidine in Young, Healthy Male Subjects , 2003, Clinical pharmacology and therapeutics.
[21] I. Zineh,et al. β1‐Adrenergic Receptor Polymorphisms and Antihypertensive Response to Metoprolol , 2003, Clinical pharmacology and therapeutics.
[22] L. Wallentin,et al. Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction. One-year follow-up of a large prospective cohort☆ , 2003 .
[23] A. Schmaier. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[24] D. Campbell. The renin-angiotensin and the kallikrein-kinin systems. , 2003, The international journal of biochemistry & cell biology.
[25] A. H. Jan Danser,et al. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? , 2003, The international journal of biochemistry & cell biology.
[26] C. Sigmund,et al. Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0150 Minireview: Overview of the Renin-Angiotensin System— , 2022 .
[27] S. de Denus,et al. Optimal digoxin concentrations for patients with heart failure. , 2003, JAMA.
[28] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[29] J. Staessen,et al. Essential hypertension , 2003, The Lancet.
[30] A. Laupacis,et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. , 2003, JAMA.
[31] Xiaotao Li,et al. Correlation of Angiotensin-Converting Enzyme Gene Polymorphism with Effect of Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitor , 2003, Journal of cardiovascular pharmacology and therapeutics.
[32] Cristina Barlassina,et al. ACE and &agr;-Adducin Polymorphism as Markers of Individual Response to Diuretic Therapy , 2003, Hypertension.
[33] Mats O. Karlsson,et al. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial , 2003, European Journal of Clinical Pharmacology.
[34] Harlan M Krumholz,et al. Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.
[35] S. Meaume,et al. Digoxin for the treatment of heart failure. , 2003, The New England journal of medicine.
[36] S. Czajkowski,et al. The effect of digoxin on the quality of life in patients with heart failure. , 2003, Journal of cardiac failure.
[37] M. Katori,et al. The Renal Kallikrein-Kinin System: Its Role as a Safety Valve for Excess Sodium Intake, and Its Attenuation as a Possible Etiologic Factor in Salt-Sensitive Hypertension , 2003, Critical reviews in clinical laboratory sciences.
[38] A L Waldo,et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.
[39] T. Katagiri,et al. Association of polymorphisms of the renin–angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough , 2002, Journal of Human Hypertension.
[40] E. Boerwinkle,et al. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. , 2002, Kidney international.
[41] Daniel Levy,et al. Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.
[42] Harlan M Krumholz,et al. Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.
[43] S. Nattel,et al. New insights into the mechanisms and management of atrial fibrillation. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[44] Michael Böhm,et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.
[45] Thomas Lumley,et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. , 2002, JAMA.
[46] S. Marullo,et al. The Myocardium-protective Gly-49 Variant of the β1-Adrenergic Receptor Exhibits Constitutive Activity and Increased Desensitization and Down-regulation* , 2002, The Journal of Biological Chemistry.
[47] J. Díez,et al. Torasemide in chronic heart failure: results of the TORIC study , 2002, European journal of heart failure.
[48] B. Suwelack,et al. Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition. , 2002, Transplantation proceedings.
[49] T. Eschenhagen,et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. , 2002, Pharmacogenetics.
[50] T. Futami,et al. Organic Anion Transporter oatp2-Mediated Interaction between Digoxin and Amiodarone in the Rat Liver , 2002, Pharmaceutical Research.
[51] Yanbin Dong,et al. Amiloride, a Specific Drug for Hypertension in Black People With T594M Variant? , 2002, Hypertension.
[52] M. Borggrefe,et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. , 2002, European journal of pharmacology.
[53] M. Esler. Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function. , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[54] L. Wallentin,et al. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study , 2002, The Lancet.
[55] H. Melhus,et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. , 2002, American journal of hypertension.
[56] C. Bouchard,et al. Polymorphism in exon 4 of the human 3 beta-hydroxysteroid dehydrogenase type I gene (HSD3B1) and blood pressure. , 2002, Biochemical and biophysical research communications.
[57] H. Melhus,et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial , 2002, Journal of hypertension.
[58] S. Hunt,et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. , 2002, Journal of the American Society of Nephrology : JASN.
[59] J. H. Patterson,et al. Clinical benefits of low serum digoxin concentrations in heart failure. , 2002, Journal of the American College of Cardiology.
[60] R. Bonow,et al. Coronary artery disease in patients with heart failure and preserved systolic function. , 2002, The American journal of cardiology.
[61] T. Arinami,et al. Identification of 33 polymorphisms in the adipocyte‐derived leucine aminopeptidase (ALAP) gene and possible association with hypertension , 2002, Human mutation.
[62] Christin Müller,et al. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. , 2002, Clinical chemistry.
[63] S. Liggett,et al. Amino Acid 49 Polymorphisms of the Human &bgr; 1 -Adrenergic Receptor Affect Agonist-Promoted Trafficking , 2002, Journal of cardiovascular pharmacology.
[64] B. Lévy,et al. Preproendothelin-1 Gene Polymorphism Is Related to a Change in Vascular Reactivity in the Human Mammary Artery In Vitro , 2002, Hypertension.
[65] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[66] T. Unger. The role of the renin-angiotensin system in the development of cardiovascular disease. , 2002, The American journal of cardiology.
[67] A. Maggioni,et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. , 2001, Journal of the American College of Cardiology.
[68] A. Pessina,et al. The Endothelin‐Aldosterone Axis and Cardiovascular Diseases , 2001, Journal of cardiovascular pharmacology.
[69] Melissa M Deer,et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. , 2001, The American journal of medicine.
[70] B. Zuraw. Bradykinin in protection against leftventricular hypertrophy , 2001, The Lancet.
[71] S. Humphries,et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response , 2001, The Lancet.
[72] L. Beilin,et al. Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy , 2001, Journal of hypertension.
[73] H. Melhus,et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients , 2001, Journal of hypertension.
[74] B. Fagerberg,et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. , 2001, Journal of the American College of Cardiology.
[75] L. Groop,et al. Polymorphism in the &bgr;1-Adrenergic Receptor Gene and Hypertension , 2001, Circulation.
[76] T. Ogihara,et al. Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.
[77] M. Ingelman-Sundberg,et al. Role of CYP2C9 polymorphism in losartan oxidation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[78] C. Held,et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan , 2001, Journal of hypertension.
[79] G. Francis,et al. Pathophysiology of chronic heart failure. , 2001, The American journal of medicine.
[80] A. Laggner,et al. Increased levels of transforming growth factor-beta1 in essential hypertension. , 2001, American journal of hypertension.
[81] R. Ravazzolo,et al. 5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. , 2001, American journal of hypertension.
[82] P. Okin,et al. Prognostic implications of left ventricular hypertrophy. , 2001, American heart journal.
[83] R. Kisabeth,et al. Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. , 2001, Mayo Clinic proceedings.
[84] E. Fleck,et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. , 2001, Journal of the American College of Cardiology.
[85] R M. Norton,et al. Clinical pharmacogenomics: applications in pharmaceutical R&D. , 2001, Drug discovery today.
[86] M. Burnier,et al. Angiotensin II Type 1 Receptor Blockers , 2001, Circulation.
[87] E. Boerwinkle,et al. C825T Polymorphism of the G Protein &bgr;3-Subunit and Antihypertensive Response to a Thiazide Diuretic , 2001, Hypertension.
[88] L. Wallentin,et al. Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.
[89] A Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Journal of lipid research.
[90] H. Black,et al. Calcium Antagonists in Hypertension , 2001, Blood pressure.
[91] E. Braunwald,et al. Congestive Heart Failure: Fifty Years of Progress , 2000, Circulation.
[92] D. Harrison,et al. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.
[93] S. Mizutani,et al. Characterization of recombinant human adipocyte-derived leucine aminopeptidase expressed in Chinese hamster ovary cells. , 2000, Journal of biochemistry.
[94] J. Díez,et al. Transforming Growth Factor &bgr; in Hypertensives With Cardiorenal Damage , 2000, Hypertension.
[95] B. Fu,et al. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. , 2000, Clinical science.
[96] M. Kyriakidis,et al. Predicting Response to Chronic Antihypertensive Treatment with Fosinopril: The Role of Angiotensin-Converting Enzyme Gene Polymorphism , 2000, Cardiovascular Drugs and Therapy.
[97] P. Puddu,et al. Endothelial dysfunction in hypertension. , 2000, Acta cardiologica.
[98] E. Salido,et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. , 2000, Kidney international.
[99] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[100] O. Pelkonen,et al. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists , 2000, European Journal of Clinical Pharmacology.
[101] A. Carcas,et al. Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. , 2000, Therapeutic drug monitoring.
[102] S. Higuchi,et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. , 2000, Therapeutic drug monitoring.
[103] N. Schork,et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. , 2000, Kidney international.
[104] Y. Tanigawara. Role of P-glycoprotein in drug disposition. , 2000, Therapeutic drug monitoring.
[105] K. Thai,et al. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. , 1999, Kidney international.
[106] P. Rosenstiel,et al. Beyond blood pressure: new roles for angiotensin II , 1999, Cellular and Molecular Life Sciences CMLS.
[107] TomohiroKatsuya,et al. Human Prostacyclin Synthase Gene and Hypertension , 1999 .
[108] B. Somer,et al. Natriuretic peptides and their therapeutic potential. , 1999, Heart disease.
[109] N. Glorioso,et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. , 1999, Hypertension.
[110] R. Schmieder,et al. 825T allele of the G-protein beta3 subunit gene (GNB3) is associated with impaired left ventricular diastolic filling in essential hypertension. , 1999, Journal of hypertension.
[111] R. Schmieder,et al. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. , 1999, Circulation.
[112] M. Domanski,et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. , 1999, Circulation.
[113] K. Fox,et al. Digoxin and mortality in chronic heart failure , 1999, The Lancet.
[114] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[115] P. Rosenbaum,et al. Invited commentary: propensity scores. , 1999, American journal of epidemiology.
[116] S. Ball,et al. Safety concerns about digoxin after acute myocardial infarction , 1999, The Lancet.
[117] L. Køber,et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. , 1999, Circulation.
[118] P. G. Fernandez,et al. Concomitant Digoxin Toxicity and Warfarin Interaction in a Patient Receiving Clarithromycin , 1999, The Annals of pharmacotherapy.
[119] S. Mizutani,et al. Molecular cloning of adipocyte-derived leucine aminopeptidase highly related to placental leucine aminopeptidase/oxytocinase. , 1999, Journal of biochemistry.
[120] J. Yoshikawa,et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. , 1999, The American journal of medicine.
[121] D. A. Mason,et al. A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.
[122] S. Ball,et al. Common polymorphisms of β1-adrenoceptor: identification and rapid screening assay , 1999, The Lancet.
[123] L Gillen,et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174 , 1999, Clinical pharmacology and therapeutics.
[124] K. Weber,et al. Angiotensin II and extracellular matrix homeostasis. , 1999, The international journal of biochemistry & cell biology.
[125] D. Healy,et al. Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. , 1999, Hypertension.
[126] M D'Amico,et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. , 1999, Hypertension.
[127] R. Raschetti,et al. Suspected adverse drug events requiring emergency department visits or hospital admissions , 1999, European Journal of Clinical Pharmacology.
[128] Y. Berger,et al. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[129] D. Healy,et al. Kidney aminopeptidase A and hypertension, part II: effects of angiotensin II. , 1999, Hypertension.
[130] M. Ingelman-Sundberg,et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.
[131] P. Padfield,et al. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. , 1998, Journal of cardiovascular pharmacology.
[132] R. Krams,et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. , 1998, Hypertension.
[133] B. Winters,et al. &ggr;‐Adrenergic Blockade Accelerates Conversion of Postoperative Supraventricular Tachyarrhythmias , 1998, Anesthesiology.
[134] P. Hasleton,et al. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. , 1998, Transplantation.
[135] H. Schunkert,et al. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. , 1998, Hypertension.
[136] X. Jeunemaître,et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. , 1998, Hypertension.
[137] R. Bonow,et al. Current medical therapy for advanced heart failure. , 1998, American heart journal.
[138] F. Cappuccio,et al. Association of hypertension with T594M mutation in β subunit of epithelial sodium channels in black people resident in London , 1998, The Lancet.
[139] T. Unger,et al. Receptors and their classification: focus on angiotensin II and the AT2 receptor , 1998, Journal of Human Hypertension.
[140] S. Borzak,et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. , 1998, American heart journal.
[141] K. Lindpaintner,et al. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. , 1998, Hypertension.
[142] Gil Vm. Hibernating myocardium. An incomplete adaptation to ischemia , 1998 .
[143] A. Russ,et al. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. , 1998, American journal of hypertension.
[144] R. Bonow,et al. Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.
[145] C. Johnston,et al. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. , 1997, American journal of hypertension.
[146] W. Trager,et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.
[147] C M O'Connor,et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. , 1997, Journal of the American College of Cardiology.
[148] G. Kajiyama,et al. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. , 1997, American journal of hypertension.
[149] Y. Tseng,et al. Nucleotide(-258) G-to-A transition variant of the liver glucokinase gene is associated with essential hypertension. , 1997, American journal of hypertension.
[150] O. Carretero,et al. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. , 1997, Hypertension.
[151] G. Bakris,et al. Renal Components of the Hypertensive Syndrome , 1997, Journal of cardiovascular risk.
[152] G P Samsa,et al. Adverse Drug Events In High Risk Older Outpatients , 1997, Journal of the American Geriatrics Society.
[153] N. Iwai,et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. , 1997, American journal of hypertension.
[154] C. Crespi,et al. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.
[155] L. Shaw,et al. Is the Volume of Distribution of Digoxin Reduced in Patients with Renal Dysfunction? Determining Digoxin Pharmacokinetics by Fluorescence Polarization Immunoassay , 1997, Pharmacotherapy.
[156] P. Grayburn,et al. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? , 1997, Journal of the American College of Cardiology.
[157] L. Jordaens,et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. , 1997, European heart journal.
[158] Bertram Pitt,et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.
[159] A. Camm,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.
[160] P. Pickkers,et al. Vascular effects of loop diuretics. , 1996, Cardiovascular research.
[161] S. Ito,et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies , 1996, Journal of hypertension.
[162] F. Cambien,et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. , 1996, Hypertension.
[163] D. Triggle. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist. , 1996, The American journal of cardiology.
[164] W. Kukovetz,et al. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion. , 1996, Circulation.
[165] Mark A. Wood,et al. Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .
[166] L. Ghiadoni,et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. , 1996, Circulation.
[167] J. H. Patterson,et al. A New Class of Antihypertensive Therapy: Angiotensin II Receptor Antagonists , 1996, Pharmacotherapy.
[168] G. Shenfield,et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.
[169] G. Bianchi,et al. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. , 1996, Journal of the American Society of Nephrology : JASN.
[170] K. Catt,et al. Angiotensin receptors and their antagonists. , 1996, The New England journal of medicine.
[171] M. Weinberger,et al. Salt sensitivity of blood pressure in humans. , 1996, Hypertension.
[172] Z. Abrahams,et al. Demonstration of an in vitro direct vascular relaxant effect of diuretics in the presence of plasma , 1996, Journal of hypertension.
[173] R. D'Agostino,et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. , 1996, Circulation.
[174] R. D'Agostino,et al. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989. , 1996, American journal of epidemiology.
[175] B. Keavney,et al. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. , 1996, Journal of hypertension.
[176] B. Winblad,et al. Use of Cardiovascular Drugs in an Older Swedish Population , 1996, Journal of the American Geriatrics Society.
[177] A. Hingorani,et al. Renin‐angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition , 1995, Journal of hypertension.
[178] H. Crijns,et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. , 1995, Journal of cardiac failure.
[179] D. Rizzoni,et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment , 1995, Journal of hypertension.
[180] M. Gheorghiade,et al. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. , 1995, Circulation.
[181] D. Reda,et al. Response to a Second Single Antihypertensive Agent Used as Monotherapy for Hypertension After Failure of the Initial Drug , 1995 .
[182] J. Avorn,et al. Epidemiology of Adverse Drug Events in the Nursing Home Setting , 1995, Drugs & aging.
[183] W. Kannel,et al. Framingham study insights into hypertensive risk of cardiovascular disease. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.
[184] S. Goldstein,et al. Relation of left ventricular chamber shape in patients with low (< or = 40%) ejection fraction to severity of functional mitral regurgitation. , 1995, The American journal of cardiology.
[185] J. Ménard,et al. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. , 1995, Circulation.
[186] M. Chang,et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. , 1995, European heart journal.
[187] R Kreutz,et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. , 1995, The New England journal of medicine.
[188] L. Ramsay,et al. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. , 1995, British journal of clinical pharmacology.
[189] W. Lewis,et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. , 1994, The American journal of cardiology.
[190] T. Ogihara,et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.
[191] S. Hohnloser,et al. Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.
[192] J. H. Patterson,et al. Oral Torsemide in Patients With Chronic Congestive Heart Failure: Effects on Body Weight, Edema, and Electrolyte Excretion , 1994, Pharmacotherapy.
[193] M. Polokoff,et al. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. , 1994, Pharmacological reviews.
[194] M. Gheorghiade,et al. Digoxin for Chronic Heart Failure: A Review of the Randomized Controlled Trials With Special Attention to the PROVED and RADIANCE Trials , 1994 .
[195] M. Bristow,et al. Economic impact of heart failure in the United States: time for a different approach. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[196] L. Tiret,et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. , 1994, Hypertension.
[197] M. Abrahamowicz,et al. Questionable prescribing for elderly patients in Quebec. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[198] K. Weber,et al. Structural remodeling in hypertensive heart disease and the role of hormones. , 1994, Hypertension.
[199] A. Everett,et al. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. , 1994, Hypertension.
[200] F. Cambien,et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[201] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[202] W. Stevenson,et al. Sudden Death Prevention in Patients With Advanced Ventricular Dysfunction , 1993, Circulation.
[203] J. W. Frank,et al. Potentially undesirable prescribing and drug use among the elderly. Measurable and remediable. , 1993, Canadian family physician Medecin de famille canadien.
[204] S. Yusuf,et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. , 1993, Journal of the American College of Cardiology.
[205] B. Uretsky,et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.
[206] Y. Tanigawara,et al. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. , 1993, The Journal of pharmacology and experimental therapeutics.
[207] T. Eschenhagen. G proteins and the heart , 1993, Cell biology international.
[208] G. Watt,et al. The angiotensin I converting enzyme gene and predisposition to high blood pressure. , 1993, Hypertension.
[209] P. Nilsson,et al. Cardiovascular risk factors in treated hypertensives—a nation‐wide, cross‐sectional study in Sweden , 1993, Journal of internal medicine.
[210] A. Taylor. Aminopeptidases: structure and function , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[211] A. Davenport,et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. , 1992, Circulation research.
[212] Y. Tanigawara,et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.
[213] Steven C. Hunt,et al. Molecular basis of human hypertension: Role of angiotensinogen , 1992, Cell.
[214] Philippe Amouyel,et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.
[215] R. Tallis,et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. , 1992, Age and ageing.
[216] G. Mancia,et al. Sympathomoderating influence of benazepril in essential hypertension , 1992, Journal of hypertension.
[217] H. Black,et al. Resistant hypertension in a tertiary care clinic. , 1991, Archives of internal medicine.
[218] H. Crijns,et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. , 1991, The American journal of cardiology.
[219] G. Shenfield,et al. A screening test for slow metabolisers of tolbutamide. , 1991, British journal of clinical pharmacology.
[220] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[221] J. Heywood,et al. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. , 1991, The American journal of cardiology.
[222] P Corvol,et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.
[223] M. Shichiri,et al. Plasma endothelin levels in hypertension and chronic renal failure. , 1990, Hypertension.
[224] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[225] J. Rawles,et al. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. , 1990, British heart journal.
[226] N. Col,et al. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. , 1990, Archives of internal medicine.
[227] G. Guyatt,et al. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. , 1990, The American journal of medicine.
[228] B. Lown,et al. Congestive heart failure induced by six of the newer antiarrhythmic drugs. , 1989, Journal of the American College of Cardiology.
[229] G. Francis. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. , 1989, American heart journal.
[230] E. Michelson,et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. , 1989, The American journal of cardiology.
[231] M. Yanagisawa,et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[232] W. Aronow,et al. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. , 1988, The American journal of cardiology.
[233] E. Chrischilles,et al. Documentation and appropriateness of prescribing for Veterans Administration ambulatory-care patients. , 1988, American journal of hospital pharmacy.
[234] J. Laragh,et al. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship. , 1988, Journal of hypertension.
[235] R. Gabriel,et al. Progressive hypokalaemia in elderly patients taking three thiazide potassium-sparing diuretic combinations for thirty-six months. , 1988, Postgraduate medical journal.
[236] K. Kjeldsen,et al. Relation of left ventricular function and Na,K-pump concentration in suspected idiopathic dilated cardiomyopathy. , 1988, The American journal of cardiology.
[237] L. Nolan,et al. Prescribing for the Elderly Part I: Sensitivity of the Elderly to Adverse Drug Reactions * , 1988, Journal of the American Geriatrics Society.
[238] G. Murray,et al. Secondary hypertension in a blood pressure clinic. , 1987, Archives of internal medicine.
[239] I. Pastan,et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[240] R. Falk,et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. , 1987, Annals of internal medicine.
[241] N. Reichek,et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.
[242] C. O. Lee,et al. Strophanthidin inotropy: role of intracellular sodium ion activity and sodium-calcium exchange. , 1985, Journal of molecular and cellular cardiology.
[243] I. Grupp,et al. Relation of sodium pump inhibition to positive inotropy at low concentrations of ouabain in rat heart muscle. , 1985, The Journal of physiology.
[244] D. Lowenthal,et al. Mechanisms of action and the clinical pharmacology of beta-adrenergic blocking drugs. , 1984, The American journal of medicine.
[245] J. Opsahl,et al. Mechanisms of elevated blood pressure in human essential hypertension. , 1984, The Medical clinics of North America.
[246] K. Swedberg,et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. , 1983, Circulation.
[247] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[248] E. Kaplinsky,et al. The Influence of Verapamil on Serum Digoxin Concentration , 1982, Circulation.
[249] W. Kannel,et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. , 1982, The New England journal of medicine.
[250] T. Lohmeier,et al. Blood pressure regulation: basic concepts. , 1981, Federation proceedings.
[251] N. Reichek,et al. Effect of diuresis on the performance of the failing left ventricle in man. , 1981, The American journal of medicine.
[252] E. Erdmann,et al. Cardiac glycoside receptor, (Na+ + K+)-ATPase activity and force of contraction in rat heart. , 1980, Biochemical pharmacology.
[253] R. Johnson,et al. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. , 1979, Cancer research.
[254] P. Poffenbarger,et al. Pharmacogenetics of Tolbutamide Metabolism in Humans , 1978, Diabetes.
[255] H. Gavras,et al. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. , 1978, The Journal of clinical endocrinology and metabolism.
[256] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[257] M. Ferrari,et al. EFFECT OF DIGOXIN ON PLASMA-RENIN-ACTIVITY IN MAN , 1976, The Lancet.
[258] F. Morady,et al. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. , 1973, Chest.
[259] E. Haber,et al. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. , 1969, The New England journal of medicine.
[260] W. Nelp,et al. RELATIONSHIP OF THE EXCRETION OF TRITIATED DIGOXIN TO RENAL FUNCTION , 1966, The American journal of the medical sciences.
[261] M. Cattell,et al. Clinical pharmacology of digoxin. , 1953, The Journal of pharmacology and experimental therapeutics.
[262] D. Ferguson,et al. A Neurohormonal Modulator in Heart Failure? , 2005 .
[263] R. Kim,et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. , 2003, Clinical pharmacology and therapeutics.
[264] H. Melhus,et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. , 2003, Pharmacogenetics.
[265] Raouf A Khalil,et al. Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney. , 2002, Seminars in nephrology.
[266] T. Ogihara,et al. Association of a sodium channel alpha subunit promoter variant with blood pressure. , 2002, Journal of the American Society of Nephrology : JASN.
[267] A. Dasgupta,et al. Bidirectional (positive/negative) interference of spironolactone, canrenone, and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin , 2002, Journal of clinical laboratory analysis.
[268] L. Ghiadoni,et al. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. , 2002, Drugs.
[269] H. Ogawa,et al. Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm , 2001, Human Genetics.
[270] E. Boerwinkle,et al. Antihypertensive pharmacogenetics: getting the right drug into the right patient. , 2001, Journal of hypertension.
[271] J. Tsai,et al. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. , 2001, Metabolism: clinical and experimental.
[272] R. Carey,et al. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. , 2000, Hypertension.
[273] T. Spector,et al. Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.
[274] A. Hingorani,et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. , 1999, Hypertension.
[275] A. Syvänen. From gels to chips: “Minisequencing” primer extension for analysis of point mutations and single nucleotide polymorphisms , 1999, Human mutation.
[276] L. Tiret,et al. Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. , 1999, Journal of molecular and cellular cardiology.
[277] A. Syvänen,et al. Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing. , 1999, Methods in molecular medicine.
[278] Arya M. Sharma,et al. Association of a human G-protein β3 subunit variant with hypertension , 1998, Nature Genetics.
[279] M. Sager,et al. Adverse drug events in hospitalized elderly. , 1998, The journals of gerontology. Series A, Biological sciences and medical sciences.
[280] R. A. Rutherford,et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. , 1998, The Journal of pharmacology and experimental therapeutics.
[281] R. Valdes,et al. Digoxin and its related endogenous factors. , 1997, Critical reviews in clinical laboratory sciences.
[282] L Zagato,et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. , 1997, Lancet.
[283] A. R. Rivera,et al. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. , 1997, Annals of emergency medicine.
[284] E. Chan,et al. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. , 1997, The Journal of allergy and clinical immunology.
[285] K. Koh,et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. , 1995, The American journal of cardiology.
[286] M. Esler. Sympathetic Nervous System: Contribution to Human Hypertension and Related Cardiovascular Diseases , 1995, Journal of cardiovascular pharmacology.
[287] J. Bolander,et al. Five-year follow-up of 589 patients treated with amiodarone. , 1993, American heart journal.
[288] M. Gheorghiade,et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. , 1993, The New England journal of medicine.
[289] F. Cappuccio,et al. Potassium supplements and potassium-sparing diuretics. A review and guide to appropriate use. , 1993, Drugs.
[290] G. Koren,et al. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. , 1993, Life sciences.
[291] B. Prichard,et al. Mode of action of beta-adrenergic blocking drugs in hypertension. , 1990, Clinical physiology and biochemistry.
[292] U. A. Meyers. Molecular genetics and the future of pharmacogenetics , 1990 .
[293] B. Dahlöf,et al. Regression of cardiovascular structural changes--a preventive strategy. , 1990, Clinical and experimental hypertension. Part A, Theory and practice.
[294] A. S. Gross,et al. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.
[295] K. Pedersen,et al. Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. , 1985, Acta medica Scandinavica. Supplementum.
[296] R. Magorien,et al. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. , 1983, American heart journal.
[297] J. Doherty,et al. The distribution and concentration of tritiated digoxin in human tissues. , 1967, Annals of internal medicine.